中文

多瑞医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.03B-34.4%
Gross profit¥0.00B
Operating income¥-0.02B
Net income¥-0.02B
Gross margin7.5%Net margin -58.6%
Revenue Q/Q+88.8%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.03B92.5%
R&D¥0.00B15.2%
SG&A¥0.02B46.5%
Tax & other¥0.00B0.5%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

新瀚新材星华新材孩子王邵阳液压百普赛斯严牌股份久盛电气百胜智能亚康股份鸿富瀚可孚医疗戎美股份

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies